Alzheimer's news - The latest biotech news from Labiotech.eu

Home Alzheimer's Page 9

Latest Posts

Alzheimers AC Immune milestone3 1

News and Trends 2 Nov 2017

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […]

November 2, 2017 - 2 minutesmins - By Alex Dale

probiodrug alzheimers disease phase iib

News and Trends 16 Oct 2017

German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb

Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […]

October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

aging gene expression scotland2 1

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

probiodrug alzheimers disease mechanism of action

News and Trends 30 Aug 2017

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is developing a therapeutic antibody with a unique mode of action against Alzheimer’s, PBD-C06. The company announced yesterday the publication in the Journal of Biological Chemistry of the detailed binding […]

August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Lipid Bilayer Crevis

News and Trends 19 Jul 2017

FREE White Paper! All You need to Know about Omics and Body Fat

What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […]

July 19, 2017 - 3 minutesmins - By External Contributor

ADVERTISEMENT

biotech hype failures ecsj2017

News and Trends 5 Jul 2017

Cutting Through the BS in Biopharma: How To Spot Hype

Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […]

July 5, 2017 - 4 minutesmins - By Evelyn Warner

Araclon Biotech Alzheimers Vaccine Spain Zaragoza

News and Trends 27 Jun 2017

A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II

Araclon Biotech will advance to Phase II with an Alzheimer’s vaccine that could succeed where many others have failed before. Araclon Biotech, in Zaragoza, Spain, has announced today the approval from the Spanish Agency of Medicines and Medical Devices to start a Phase II trial testing its Alzheimer’s vaccine in 120 patients in 22 centers across Europe. The […]

June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

early stage startup battle refresh 1

News and Trends 26 Jun 2017

Videos: Who won the Refresh Early-Stage Startup Battle? The Bonsai goes to…

As you might have read in our recap, we had not one but two startup battles for the last edition of Refresh. Watch the companies’ pitches below! Up first was Cambridge Cancer Genomics, which uses AI to design personalised DNA-based tests to help clinicians to better track their patients’ responses to cancer drugs in order to make […]

June 26, 2017 - 2 minutesmins - By Evelyn Warner

Probiodrug Alzheimers PQ912 Phase IIa

News and Trends 12 Jun 2017

German Biotech Unveils Positive Phase II Results for Alzheimer’s

Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead candidate PQ912 in patients with early Alzheimer’s Disease. The German biotech Probiodrug is pioneering new approaches to eliminate pyroglutamate (pGlu)-Abeta, a peptide that has been linked to the formation of toxic oligomers involved in Alzheimer’s disease. Now, the biotech came out […]

June 12, 2017 - 3 minutesmins - By Melanie De Almeida

Romanova Natali

Interview 10 Apr 2017

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer’s Disease without any success to show for its efforts. Now the sixth leading cause of death across all age groups, […]

April 10, 2017 - 7 minutesmins - By Evelyn Warner

Asceneuron ASN120290 PSP Phase I

News and Trends 6 Apr 2017

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

ADVERTISEMENT